Literature DB >> 2434529

Hemoglobin Mississippi (beta 44ser----cys). Studies of the thalassemic phenotype in a mixed heterozygote with beta +-thalassemia.

M H Steinberg, J G Adams, W T Morrison, D J Pullen, R Abney, A Ibrahim, R F Rieder.   

Abstract

Hemoglobin Mississippi (HbMS: beta 44ser----cys) has anomalous properties that include disulfide linkages with normal beta-, delta-, gamma-, and alpha-chains, and the formation of high molecular weight multimers. While heterozygotes for HbMS are clinically and hematologically normal and carriers of the beta +-thalassemia gene in our family had mild microcytic anemia, the proband with HbMS-beta +-thalassemia had a hemoglobin level of 7 g/dl, mean corpuscular volume (MCV) of 68 fl, reticulocytes of 2-6%, HbF of 18%, marked anisocytosis and poikilocytosis, and splenomegaly, all features of thalassemia intermedia. With oxidant stress, her erythrocytes developed multiple dispersed Heinz bodies, but HbMS was only mildly unstable. HbMS was susceptible to proteolytic degradation in the presence of ATP. The unexpectedly severe clinical findings in HbMS-beta +-thalassemia may result from the proteolytic digestion of HbMS, as well as the excessive alpha-chains characteristic of beta +-thalassemia, which combined provide the increment of cellular damage that results in the phenotype of thalassemia intermedia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434529      PMCID: PMC424211          DOI: 10.1172/JCI112890

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Estimation of small percentages of foetal haemoglobin.

Authors:  K BETKE; H R MARTI; I SCHLICHT
Journal:  Nature       Date:  1959-12-12       Impact factor: 49.962

2.  beta-Thalassemia present in cis to a new beta-chain structural variant, Hb Vicksburg [beta 75 (E19)Leu leads to 0].

Authors:  J G Adams; M H Steinberg; M V Newman; W T Morrison; E J Benz; R Iyer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

3.  Hemoglobin Petah Tikva (alpha 110 ala replaced by asp): a new unstable variant with alpha-thalassemia-like expression.

Authors:  G R Honig; M Shamsuddin; R Zaizov; M Steinherz; I Solar; C Kirschmann
Journal:  Blood       Date:  1981-04       Impact factor: 22.113

4.  Globin structural mutant alpha 125Leu leads to Pro is a novel cause of alpha-thalassaemia.

Authors:  M Goossens; K Y Lee; S A Liebhaber; Y W Kan
Journal:  Nature       Date:  1982-04-29       Impact factor: 49.962

5.  Rapid destruction of newly synthesized excess beta-globin chains in HbH disease.

Authors:  G B Sancar; M M Cedeno; R F Rieder
Journal:  Blood       Date:  1981-05       Impact factor: 22.113

6.  Localization of the site of recombination in formation of the Lepore Boston globin gene.

Authors:  M Baird; H Schreiner; C Driscoll; A Bank
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

7.  Properties of abnormal proteins degraded rapidly in reticulocytes. Intracellular aggregation of the globin molecules prior to hydrolysis.

Authors:  Y Klemes; J D Etlinger; A L Goldberg
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

8.  Hemoglobin Suan-Dok (alpha 2 109 (G16) Leu replaced by Arg beta 2): an unstable variant associated with alpha-thalassemia.

Authors:  T Sanguansermsri; S Matragoon; L Changloah; G Flatz
Journal:  Hemoglobin       Date:  1979       Impact factor: 0.849

9.  Abnormal red cell membrane proteolytic activity in severe heterozygous beta-thalassemia.

Authors:  S K Ballas; E R Burka; F M Gill
Journal:  J Lab Clin Med       Date:  1982-02

10.  Excess alpha chains are lost from beta-thalassemic reticulocytes by proteolysis.

Authors:  U Testa; N Hinard; Y Beuzard; A Tsapis; F Galacteros; P Thomopoulos; J Rosa
Journal:  J Lab Clin Med       Date:  1981-09
View more
  1 in total

1.  Two missense mutations in the beta-globin gene can cause severe beta thalassemia. Hemoglobin Medicine Lake (beta 32[B14]leucine-->glutamine; 98 [FG5] valine-->methionine).

Authors:  M B Coleman; Z H Lu; C M Smith; J G Adams; A Harrell; M Plonczynski; M H Steinberg
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.